Takeda recalls anti-inflammatory Dasen in Japan due to efficacy
Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), says it has voluntarily recalled Dasen (serrapeptase) 5mg and 10mg tablets, and 1% granules, its anti-inflammatory enzyme preparations sold in Japan, starting on February 21.
In the double-blind studies that have been conducted to compare Dasen with placebo no statistical significant differences were found. Based on the results of these, the Committee on Reevaluation of the Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labor and Welfare of Japan held a meeting on January 19, 2011, to consider the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze